<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259269</url>
  </required_header>
  <id_info>
    <org_study_id>Partners IRB 2015P001669</org_study_id>
    <nct_id>NCT03259269</nct_id>
  </id_info>
  <brief_title>Expand New Drugs for TB [endTB]</brief_title>
  <official_title>endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Partners in Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Médecins Sans Frontières, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Interactive Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epicentre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Partners in Health</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will examine the safety and efficacy of bedaquiline and delamanid
      used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB. The
      information gathered in this study will inform doctors how best to use these TB drugs in the
      future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>End of treatment outcome</measure>
    <time_frame>20 - 24 months of treatment</time_frame>
    <description>Final outcomes: cured, treatment completed, treatment failed, lost to follow-up, died, not evaluated</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>Bedaquiline and companion WHO Group 5 drugs</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Delamanid and companion WHO Group 5 drugs</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is a non-intervention observational study</intervention_name>
    <description>No applicable intervention; this is a secondary data analysis observational study.</description>
    <arm_group_label>Bedaquiline and companion WHO Group 5 drugs</arm_group_label>
    <arm_group_label>Delamanid and companion WHO Group 5 drugs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All MDR-TB patients started on treatment containing a new TB drug (bedaquiline or
        delamanid) and enrolled in clinical care within the endTB Project.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient who receives a treatment regimen containing bedaquiline or delamanid at an
             endTB site will be invited to participate in this observational study, regardless of
             age or gender.

          -  Any patient who signs the study informed consent form will be included in the study.

        Exclusion Criteria:

          -  Refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah McAnaw</last_name>
    <email>smcanaw@pih.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Chang</last_name>
    <email>eva_chang@hms.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Treatment Centre for Tuberculosis, Abovian, Armenia</name>
      <address>
        <city>Abovyan</city>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naira Khachatryan, MD</last_name>
      <email>msff-erevan-medco@paris.msf.org</email>
    </contact>
    <investigator>
      <last_name>Armen Hayrapetyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamidah Hussain, MBBS, MSc</last_name>
      <email>hamidah.hussain@irdresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Manzur ul-Alam, MD</last_name>
      <email>manzur.ulalam@irdresearch.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Republican Research and Practical Centre for Pulmonology and Tuberculosis</name>
      <address>
        <city>Minsk</city>
        <zip>220053</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoseph Tassew, MD</last_name>
      <email>russia-medco@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Alena Skrahina, MD, PhD, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bishoftu Hospital</name>
      <address>
        <city>Bishoftu</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andargachew Kumsa, MD</last_name>
      <email>AKumsa@pih.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center for Tuberculosis and Lung Diseases</name>
      <address>
        <city>Tbilisi</city>
        <zip>0101</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tinatin Kotrikadze, MD</last_name>
      <email>msff-tbilisi-medco@paris.msf.org</email>
    </contact>
    <investigator>
      <last_name>Zara Avaliani, MPH, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RS Islam Jakarta Cempaka Putih</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fauziah Asnely Putri, MD, MPH</last_name>
      <email>fauziah.putri@irdresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Center for Phthisionpulmonology</name>
      <address>
        <city>Almaty</city>
        <zip>050010</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yerkebulan Algozhin, MD</last_name>
      <email>ealgozhin@pih.org</email>
    </contact>
    <investigator>
      <last_name>Elmira Berikova, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSF Tuberculosis clinic, Mathare, Nairobi, Kenya</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Wanjala, MD</last_name>
      <email>msff-nairobi-medco@paris.msf.org</email>
    </contact>
    <investigator>
      <last_name>Maureen Kamene, MD, MBCHB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kara-Suu District TB hospital</name>
      <address>
        <city>Kara-Suu</city>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayk Karakozian, MD</last_name>
      <email>MSFCH-Kyrgyzstan-Medco@geneva.msf.org</email>
    </contact>
    <investigator>
      <last_name>Kadyrov Abdullaat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Botshabelo Hospital</name>
      <address>
        <city>Maseru</city>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwonjune Seung, MD</last_name>
      <email>kjseung@pih.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aung San Tuberculosis Hospital</name>
      <address>
        <city>Yangon</city>
        <country>Myanmar</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jarmila Kliescikova, MD</last_name>
      <email>myanmar-medco@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Si Tu Aung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Indus Hospital, Karachi</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabia Mashkoor, MD</last_name>
      <email>rabia.mashkoor@ghd.ihn.org.pk</email>
    </contact>
    <investigator>
      <last_name>Sana Adnan, MBBS, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Chest Diseases, Kotri</name>
      <address>
        <city>Kotri</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabia Mashkoor, MD</last_name>
      <email>rabia.mashkoor@ghd.ihn.org.pk</email>
    </contact>
    <investigator>
      <last_name>Sana Adnan, MBBS, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulab Devi Chest Hospital, Lahore</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabia Mashkoor, MD</last_name>
      <email>rabia.mashkoor@ghd.ihn.org.pk</email>
    </contact>
    <investigator>
      <last_name>Sana Adnan, MBBS, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Socios en Salud</name>
      <address>
        <city>Carabayllo</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Contreras, BS</last_name>
      <email>ccontreras_SES@pih.org</email>
    </contact>
    <investigator>
      <last_name>Leonid Lecca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Dinuzulu Hospital</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munira Khan, MBCHB</last_name>
      <email>munira.khan@irdresearch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Bangladesh</country>
    <country>Belarus</country>
    <country>Ethiopia</country>
    <country>Georgia</country>
    <country>Indonesia</country>
    <country>Kazakhstan</country>
    <country>Kenya</country>
    <country>Kyrgyzstan</country>
    <country>Lesotho</country>
    <country>Myanmar</country>
    <country>Pakistan</country>
    <country>Peru</country>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://endtb.org/</url>
    <description>endTB Project website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bedaquiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

